Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The complexity of the disease, immunotherapy developments, and effective therapies have influences on market dynamics of pharmaceutical treatments for Pemphigus Vulgaris. These blisters are painful leading to medical approaches that cater to its symptoms and underlying autoimmune reactions in patients. There are various factors that shape this particular market such as scarcity of the disease, evolving immunomodulatory drugs landscape and the need to improve quality of patients’ lives.
Market dynamics of pharmaceutical treatments for Pemphigus Vulgaris is shaped by its rarity. It represents a small niche within broader pharma. This combined with the chronic nature of the severe condition requires drugs that suppress immune response into blister forming process. Such companies often concentrate on biologics and immunomodulators aimed at eliminating specific autoimmune mechanisms involved in Pemphigus Vulgaris.
A significant portion of the pharmaceutical market for Pemphigus Vulgaris treatment is driven by advances in immunotherapy. The use of systemic corticosteroids and other types of immunosuppressive drugs has long been used as a way of controlling autoimmunity problems. However, their side effects and long-term outcomes have propelled the adoption of such biologics and targeted therapies instead. Monoclonal antibodies like rituximab offer hope because they target B cells which cause this autoimmune reaction. There are several different products available depending upon individual needs or responses.
Moreover, ongoing research into underpinning mechanisms for developing novel treatments also affects these dynamics accordingly. In light with this knowledge development, drug companies strive to identify new therapeutic targets as well as novel strategies to be applied when treating it. The result is larger numbers clinical trials more research studies thus providing opportunities additional options healthcare providers can recommend to their patients. However, there is still an active market in this space with new treatments emerging that are shown to work for Pemphigus Vulgaris without causing too many side effects.
Regulatory considerations play a major role in the dynamics of pharmaceutical therapies for Pemphigus Vulgaris. Authorities have strict requirements on drug approval and marketing, which includes aspects of safety and quality maintenance. This would mean close scrutiny and monitoring when applying new drugs to treat autoimmune diseases. In order to be able to bring innovative treatments into the market while respecting existing norms, pharmaceutical companies adapt their products depending on regulatory guidelines thus enhancing trustworthiness of Pemphigus Vulgaris treatments at large.
The focus on patient-centric care in healthcare landscape also influences the market dynamics of pemphigus vulgaris treatments. Patients with autoimmune disorders such as pemphigus vulgaris face various challenges while managing them. The industry develops formulations that not only target autoimmunity processes but also make it easy for clients to use safely at home. There are patients support programs as well as ways people can get educated on management issues including how best they can apply medications.
In the pharmaceutical market for Pemphigus Vulgaris treatments, economic considerations also come into play. The costs of new biologics and targeted therapies can be very high, raising questions about accessibility and affordability. In order to address these concerns, there are some areas that the market considers including cost-effective formulations, biosimilars and patient assistance programs which guarantee access to innovative treatments without imposing an unjustified financial burden on patients.
Pemphigus Vulgaris Market Highlights:
Pemphigus Vulgaris Market is expected to grow USD 4.26 Million at a CAGR 9.10% during the forcast period 2023 to 2030.Pemphigus Vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the healthy cells and causes skin problems. Pemphigus Vulgaris affects both men and women, but middle- and old-aged people are more likely to develop this condition.
Market Dynamics
The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, rising bacterial and viral infection, and the growing prevalence of cancer. The side effects associated with the medication and increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment, unfavorable reimbursement situation, and lack of awareness are expected to restrain the market growth
Pemphigus vulgaris is one of the most life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe affecting approximately 0.7 to 5 people per 1,000,000 each year in the overall population. It was also mentioned that pemphigus foliaceus a form of pemphigus vulgaris has a high prevalence in Africa and some rural areas in the world.
According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were diagnosed with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the globe is expected to drive market growth during the forecast period from 2023 to 2030.
Global Pemphigus Vulgaris Market Share, by Type, 2017 (%) Â 
Source: MRFR Analysis
Segmentation
The global pemphigus vulgaris market, by treatment, has been segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy. Based on the route of administration, the market has been classified as intravenous, subcutaneous, and oral. By end user, the global pemphigus vulgaris market has been categorized as hospitals & clinics, specialty dermatology clinics, and research & academic laboratories.
Global Pemphigus Vulgaris Market Share, by Region, 2017 (%) Â 
Source: MRFR Analysis
Regional Analysis
The global pemphigus vulgaris market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas accounted for the largest market share in 2030 and is estimated to dominate the global pemphigus vulgaris market. The Americas is anticipated to reach USD 426 million by 2030 at a CAGR of 9.10% from 2023 to 2030. The Americas accounts for the largest regional market owing to the increasing prevalence of pemphigus vulgaris, increasing geriatric population, and raising funding for the research & development of skin diseases. According to the National Center for Biotechnology Information 2014, it was predicted that the prevalence of pemphigus vulgaris in the US is in the range of 0.76 to 5 new cases per million every year. Also, according to the International Pemphigus & Pemphigoid Foundation, it was projected that approximately 2,500 people in the US suffered from pemphigus disorder in 2017.
Europe accounted for the second-largest market share in 2017 due to extensive R&D for pemphigus vulgaris, increasing funding, and growing adoption of the technology within the region. Asia-Pacific is expected to contribute to the market growth for pemphigus vulgaris during the forecast period owing to rising therapeutic demand for pemphigus vulgaris and rapidly evolving healthcare sector. On the other hand, the Middle East & Africa is expected to observe slow growth due to low per capita disposable incomes, lack of awareness, and less exposure to healthcare services in this region.
Key Players
The prominent players in the global pemphigus vulgaris market are Almirall, SA, Argenx SE, Biogen Inc., F. Hoffmann-La Roche, Syntimmune, Pfizer Inc., Novartis AG, Sanofi, Janssen Global Services, LLC, and Principia Biopharma.
Some of the key strategies followed by players operating in the global pemphigus vulgaris market were innovation, product development, and acquisition & mergers.
- In December 2017, Almirall SA and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.
- In January 2018, Pandion Therapeutics, a start-up led by former executives at Pfizer and Biogen, attracted USD 58 million in financing for the development of a new class of drugs that could tweak the immune system without triggering significant side effects.
- In February 2018, Roche announced that the US Food and Drug Administration (FDA) had accepted the company’s supplemental biologics license application (SBLA) and granted priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Market Segmentation
Global Pemphigus Vulgaris Market, by Treatment
- Corticosteroids
- Immunosuppressants
- Biological Therapies
- Intravenous Immunoglobulin (IVIG) Therapy
Global Pemphigus Vulgaris Market, by Route of Administration
- Intravenous
- Subcutaneous
- Oral
Global Pemphigus Vulgaris Market, by End User
- Hospitals & Clinics
- Specialty Dermatology Clinics
- Research & Academic Laboratories
Global Pemphigus Vulgaris Market, by Region
- Americas
- North America
- US
- Canada
- Europe
- Western America
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western America
- Asia-Pacific
- China
- Japan
- Australia
- Republic of Korea
- India
- Rest of Asia-Pacific
- Rest of the world
Available Additional Customizations
- Treatment cost analysis
- Epidemiology data
- Clinical trials data
Intended Audience
- Clinical laboratories
- Pharmaceutical market
- Government organizations
- Research & consulting firms
- Biotechnology companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
